Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio

Alderman, James; Pasternak, Richard C.; Sacks, Frank M.; Smith, H S; Monrad, E. Scott; Grossman, William

doi:10.1016/0002-9149(89)90754-6

Cited by 77 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nicotinic acid (niacin), a water-soluble B vitamin, is the single most effective pharmacologic agent currently available for raising HDL-C. 103 Therapy with niacin results in a 15%-35% increase in HDL-C, with the highest increases reported with doses of 1-2 g daily. 104 Niacin additionally provides significant decreases in LDL-C and TG levels, 105 and up to a 39% reduction in lipoprotein(a) levels.…”

Section: Niacinmentioning

confidence: 99%

Raising HDL cholesterol in women

Eapen

Kalra²,

Rifai³

et al. 2009

IJWH

View full text Add to dashboard Cite

High-density lipoprotein cholesterol (HDL-C) concentration is essential in the determination of coronary heart disease (CHD) risk in women. This is especially true in the postmenopausal state, where lipid profiles and CHD risk mimic that of age-matched men. Thus, interventions designed to reduce CHD risk by raising HDL-C levels may have particular significance during the transition to menopause. This review discusses HDL-C-raising therapies and the role of HDL in the primary prevention of CHD in women. Lifestyle-based interventions such as dietary change, aerobic exercise regimens, and smoking cessation are initial steps that are effective in raising HDL-C, and available data suggest women respond similarly to men with these interventions. When combined with pharmacotherapy, the effects of these lifestyle alterations are further amplified. Though studies demonstrating gender-specific differences in therapy are limited, niacin continues to be the most effective agent in raising HDL-C levels, especially when used in combination with fibrate or statin therapy. Emerging treatments such as HDL mimetic therapy show much promise in further raising HDL-C levels and improving cardiovascular outcomes.

show abstract

Section: Niacinmentioning

confidence: 99%

Raising HDL cholesterol in women

Eapen

Kalra²,

Rifai³

et al. 2009

IJWH

View full text Add to dashboard Cite

show abstract

“…It also increases HDL-C by inhibiting apoprotein A-catabolism. The percent decrease in TG by the administration of a nicotinate alone (3.0 g/day) is 26% 77) . A preventive effect of nicotinates against CAD has also been demonstrated by a large-scale clinical study 78) .…”

Section: ) Nicotinates: Niceritrol Nicomol Tocopherolmentioning

confidence: 96%

Treatment - Drug Therapy

Teramoto

Sasaki

Ueshima

et al. 2008

JAT

View full text Add to dashboard Cite

“…In addition, these drugs exert HDL-C-increasing effects by inhibiting apolipoprotein A-I catabolism. The rate of decrease in TG following nicotinic acid monotherapy (3.0 g/day) is 26% 32) . Nicotinic acid derivatives also have Lp(a)-lowering effects [33][34][35] .…”

Section: ) Nicotinic Acid Derivatives: Niceritrol Nicomol and Tocopmentioning

confidence: 99%